Immuno-oncology continued to dominate some of the largest alliances, including deals for bispecific antibodies as well as small molecules. Once again, cancer was the leading therapeutic area by volume in both partnerships and financings. Pfizer Inc. rebounded from its failed tax inversion deal attempt in 2015 by acquiring Medivation Inc., maker of the prostate cancer drug Xtandi (enzalutamide), in the largest M&A of 2016.[See Deal] Indeed, oncology was well represented in the top acquisitions of the year, and in financings.
We focus here on the dealmakers, showing which companies dominated the landscape in terms of deal volume and value, as...
